Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853307 · ClinicalTrials.gov registry record · Phase 2
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00853307 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT00853307, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomas.
Interventions
- DRUG Alisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-03-23 |
| Est. Completion | 2011-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853307
The ClinicalTrials.gov registry entry for NCT00853307 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alisertib is the first listed.
NCT00853307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853307 about?
NCT00853307 is a clinical study titled "MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma". The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomas.
What is the current status of trial NCT00853307?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2009-03-23. Estimated completion is 2011-01-27.
What interventions are being tested in trial NCT00853307?
The interventions under investigation include: Alisertib (DRUG).
Who is sponsoring clinical trial NCT00853307?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.